---
title: "Benitec Biopharma | 8-K: FY2026 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286414116.md"
datetime: "2026-05-14T12:11:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286414116.md)
  - [en](https://longbridge.com/en/news/286414116.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286414116.md)
---

# Benitec Biopharma | 8-K: FY2026 Q3 Revenue: USD 0

Revenue: As of FY2026 Q3, the actual value is USD 0.

EPS: As of FY2026 Q3, the actual value is USD -0.24.

EBIT: As of FY2026 Q3, the actual value is USD -15.18 M.

### Financial Highlights (Three Months Ended March 31, 2026 vs. 2025)

#### Total Expenses

Benitec Biopharma Inc.’s total expenses for the three months ended March 31, 2026, were $13,582 thousand, a decrease from $15,335 thousand for the same period in 2025.

#### Research and Development Expenses

Research and development expenses for Benitec Biopharma Inc. were $6,298 thousand for the three months ended March 31, 2026, compared to $6,495 thousand for the three months ended March 31, 2025.

#### General and Administrative Expenses

General and administrative expenses for Benitec Biopharma Inc. decreased to $7,284 thousand for the three months ended March 31, 2026, from $8,840 thousand in the prior year’s comparable period.

#### Loss from Operations

The loss from operations for Benitec Biopharma Inc. for the three months ended March 31, 2026, was -$13,582 thousand, an improvement from a loss of -$15,335 thousand for the three months ended March 31, 2025.

#### Net Loss Attributable to Shareholders

Net loss attributable to shareholders for Benitec Biopharma Inc. for the three months ended March 31, 2026, was -$11,935 thousand, compared to -$14,501 thousand for the three months ended March 31, 2025.

### Financial Highlights (Nine Months Ended March 31, 2026 vs. 2025)

#### Net Loss Attributable to Shareholders

For the nine months ended March 31, 2026, Benitec Biopharma Inc.’s net loss attributable to shareholders was -$32,737 thousand, compared to -$29,112 thousand for the nine months ended March 31, 2025.

### Cash Position

#### Cash and Cash Equivalents

As of March 31, 2026, Benitec Biopharma Inc. reported cash and cash equivalents of $184,761 thousand.

### Operational Update and Outlook

Benitec Biopharma Inc. anticipates updated interim clinical study results for its BB-301 program’s Cohort 1 and Cohort 2 patients in the second half of 2026. The company plans to engage with the U.S. Food and Drug Administration (FDA) mid-year to finalize the BB-301 pivotal study design. Benitec Biopharma Inc. is well-capitalized to fund the BB-301 program through the completion of its pivotal study.

### Related Stocks

- [BNTC.US](https://longbridge.com/en/quote/BNTC.US.md)

## Related News & Research

- [Benitec Biopharma Limited (NASDAQ:BNTC) Given Average Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/294018130.md)
- [FFIV: Q3 FY26 revenue grew 11% year-over-year, with raised FY26 guidance and strong product momentum](https://longbridge.com/en/news/293970097.md)
- [Plexus Q3 revenue hits record, beating estimates on new programs' success](https://longbridge.com/en/news/294259938.md)
- [SRX Global amends 8-K to correct CFO Carolina Martinez misidentified as CEO](https://longbridge.com/en/news/294232884.md)
- [IES Holdings Q3 revenue rises on strong data center demand](https://longbridge.com/en/news/294508975.md)